Myriad Asset Management US’s CONMED CNMD Stock Holding History

Myriad Asset Management US’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,940	Closed	-$282K	–	29
2022 Q2	$282K	Buy	+2,940	New	+$353K	0.07%	38

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Myriad Asset Management US's CNMD Position: Q3 2022 in Review

Myriad Asset Management US sold out of CONMED (CNMD) in Q3 2022, closing a stake of 2,940 shares — an estimated $282K sold.

Myriad Asset Management US first reported a position in CNMD in Q2 2022 and held it in 1 quarter. The position peaked at $282K in Q2 2022. 252 funds tracked by Wall St. Rank hold CNMD as of Q3 2022.

Myriad Asset Management US reported no remaining CONMED position as of Q3 2022 after selling out during the quarter.
Myriad Asset Management US sold 2,940 CONMED shares in Q3 2022, an estimated $282K.
Myriad Asset Management US first reported a position in CONMED in Q2 2022 and held it in 1 quarter.
Myriad Asset Management US's CONMED position peaked at $282K in Q2 2022.
252 funds tracked by Wall St. Rank held CONMED as of Q3 2022.

Based on Myriad Asset Management US's 13F filing for Q3 2022, filed 14 Nov 2022.